QuickView for Tace;jsessionid=2B370222F07357542C739905C1140B15;jsessionid=73455E8F1A6DE2FD4F7DF32E788E1054;jsessionid=BDD3FC5CEF89F5528113F5EC3B91E499;jsessionid=8F8E5A140C83A813B9A75481DDC7307D;jsessionid=8378ACDB7CD62D0363487D57783EC7C1;jsessionid=1843BECF6914F4A7EF29EE76BD8350BC;jsessionid=0E4977B2C021EC563D53CBACB7B89667;jsessionid=996F0F53DDA5FA88FFA50B462BEFEC35;jsessionid=D606D4800469A71CC15C0832EAE67BA4 (gene)

1. The metalloprotease ADM-4/ADAM17 promotes axonal repair.
2. ADAM17: A novel treatment target for aneurysms.
3. Phylogeny and expression of ADAM10 and ADAM17 homologs in lamprey.
4. Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells.
5. The ADAM17 sheddase complex regulator iTAP/Frmd8 modulates inflammation and tumor growth.

There were no clinical trials for Tace;jsessionid=2B370222F07357542C739905C1140B15;jsessionid=73455E8F1A6DE2FD4F7DF32E788E1054;jsessionid=BDD3FC5CEF89F5528113F5EC3B91E499;jsessionid=8F8E5A140C83A813B9A75481DDC7307D;jsessionid=8378ACDB7CD62D0363487D57783EC7C1;jsessionid=1843BECF6914F4A7EF29EE76BD8350BC;jsessionid=0E4977B2C021EC563D53CBACB7B89667;jsessionid=996F0F53DDA5FA88FFA50B462BEFEC35;jsessionid=D606D4800469A71CC15C0832EAE67BA4